| 000 | 01326 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250515040612.0 | ||
| 264 | 0 | _c20060918 | |
| 008 | 200609s 0 0 eng d | ||
| 022 | _a1527-7755 | ||
| 024 | 7 |
_a10.1200/JCO.2006.07.5325 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBleyer, Archie | |
| 245 | 0 | 0 |
_aEpoetin versus darbepoetin conundrum compromise. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cSep 2006 |
||
| 300 |
_ae46 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 |
_aAnemia, Hypochromic _xdrug therapy |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aDarbepoetin alfa |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aEpoetin Alfa |
| 650 | 0 | 4 |
_aErythropoietin _xadministration & dosage |
| 650 | 0 | 4 |
_aHematinics _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xcomplications |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 24 _gno. 25 _gp. e46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2006.07.5325 _zAvailable from publisher's website |
| 999 |
_c16528761 _d16528761 |
||